Cytokinetics Inc (CYTK) FinancialsCYTKCytokinetics Inc

Evaluating the bottom line, Cytokinetics, Incorporated maintains a gross margin of 80.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -625.95%, while the net margin is -694.39%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CYTK converts its operational activities into shareholder value.

In the context of the broader market, CYTK competes directly with industry leaders such as TGTX and PTGX. With a market capitalization of $8.82B, it holds a significant position in the sector. When comparing efficiency, CYTK's gross margin of 80.46% stands against TGTX's 82.86% and PTGX's 100.00%. Such benchmarking helps identify whether Cytokinetics, Incorporated is trading at a premium or discount relative to its financial performance.

Cytokinetics has shown fluctuating revenue, with Q2 2026 revenue at $28,624,000, but it continues to report substantial net losses, including -198,762,000 in Q2 2026. Gross margins have decreased from 100% to 80.46% in the same period, indicating potential challenges in maintaining profitability.